CA3185526A1 - Method of treatment of neutrophil-driven inflammatory pathologies - Google Patents

Method of treatment of neutrophil-driven inflammatory pathologies

Info

Publication number
CA3185526A1
CA3185526A1 CA3185526A CA3185526A CA3185526A1 CA 3185526 A1 CA3185526 A1 CA 3185526A1 CA 3185526 A CA3185526 A CA 3185526A CA 3185526 A CA3185526 A CA 3185526A CA 3185526 A1 CA3185526 A1 CA 3185526A1
Authority
CA
Canada
Prior art keywords
seq
therapeutic peptide
svl4
amino acid
neutrophil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3185526A
Other languages
English (en)
French (fr)
Inventor
Laura L. Eggink
J. Kenneth Hoober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Susavion Biosciences Inc
Original Assignee
Susavion Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susavion Biosciences Inc filed Critical Susavion Biosciences Inc
Publication of CA3185526A1 publication Critical patent/CA3185526A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3185526A 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies Pending CA3185526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057741P 2020-07-28 2020-07-28
US63/057,741 2020-07-28
PCT/US2021/038999 WO2022026092A2 (en) 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies

Publications (1)

Publication Number Publication Date
CA3185526A1 true CA3185526A1 (en) 2022-02-03

Family

ID=80038122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3185526A Pending CA3185526A1 (en) 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies

Country Status (7)

Country Link
US (1) US20230285505A1 (enExample)
EP (1) EP4181942A4 (enExample)
JP (1) JP2023536815A (enExample)
CN (1) CN116194143A (enExample)
AU (1) AU2021318793A1 (enExample)
CA (1) CA3185526A1 (enExample)
WO (1) WO2022026092A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
WO2013096829A2 (en) * 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US9155796B2 (en) * 2012-12-04 2015-10-13 Susavion Biosciences, Inc. Hydrogels with covalently linked polypeptides
CA2971471C (en) * 2014-12-19 2023-04-18 Susavion Biosciences, Inc. Immunotherapy treatments and compositions
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Also Published As

Publication number Publication date
US20230285505A1 (en) 2023-09-14
JP2023536815A (ja) 2023-08-30
EP4181942A4 (en) 2024-10-02
WO2022026092A2 (en) 2022-02-03
AU2021318793A1 (en) 2023-02-09
WO2022026092A3 (en) 2022-03-03
WO2022026092A9 (en) 2022-04-28
CN116194143A (zh) 2023-05-30
EP4181942A2 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
Kim et al. Skin barrier dysfunction and filaggrin: Y. Kim, K.-M. Lim
Brogden et al. The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation
RU2429004C2 (ru) Способы регуляции медиаторов воспаления и пептиды, используемые в них
Colin et al. Macrophage phenotypes in atherosclerosis
US20210228652A1 (en) Antimicrobial therapy
Ramadan et al. Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation
Yu et al. LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2
JP6889201B2 (ja) Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
EP2053915B1 (en) Peptides for attenuating release of inflammatory mediators
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
BRPI0915973A2 (pt) uso de uma beta defensina humana
Zhang et al. Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation
Meng et al. Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract
US20230285505A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
KR101778169B1 (ko) 미엘린염기성단백질의 올리고펩티드 단편을 함유하는 리포솜, 의약조성물 및 다발성경화증의 치료법
HK40090910A (en) Method of treatment of neutrophil-driven inflammatory pathologies
US10143718B2 (en) Covalent inhibitors of dual oxidase 1 (DUOX 1)
US20260055139A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
CA3174870A1 (en) Compositions and methods for treating bacterial infections
US20250222064A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
WO2020072805A1 (en) Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
US20260021165A1 (en) Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease
Chen et al. Cadherin-26 drives macrophage alternative activation via suppressing STUB1-mediated IL-4Rα ubiquitination in asthma
아지즈 GPCR19 agonist (TDCA) efficacy and mode of action in atopic dermatitis and rosacea
del Río Oliva Targeting the immunoproteasome and VCP/p97 in autoimmune disorders and viral infection

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241010

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260224

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728